Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5NIH 3NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Monocytic, Acute 1

Interventions

Magnetic Resonance Spectroscopy 287Specimen Handling 285pembrolizumab 258Cyclophosphamide 237Radiotherapy 233Nivolumab 187Cisplatin 174Biopsy 170Carboplatin 155Radiosurgery 142fludarabine 131Blood Specimen Collection 130Surveys and Questionnaires 120Gemcitabine 120Paclitaxel 115venetoclax 114Standard of Care 112Dexamethasone 105Bevacizumab 98Radiation 97Rituximab 92Oxaliplatin 89Cytarabine 88Capecitabine 88Drug Therapy 86Ipilimumab 85Doxorubicin 83durvalumab 81atezolizumab 76fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Liposomes × 90 days × Clear all
NCT03629171 2026-05-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04915612 2026-05-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04195945 2026-05-14

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
60 enrolled 19 charts
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Thomas Jefferson University

Phase 1 Recruiting
24 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡